$5.72
1.57%
Downside
Day's Volatility :5.22%
Upside
3.7%
43.88%
Downside
52 Weeks Volatility :86.35%
Upside
75.68%
Period | Eagle Pharmaceuticals Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 37.98% | 6.5% | 0.0% |
6 Months | 6.1% | 7.1% | 0.0% |
1 Year | -69.42% | 9.8% | 0.0% |
3 Years | -87.93% | 14.2% | -20.2% |
Market Capitalization | 68.0M |
Book Value | $19.25 |
Earnings Per Share (EPS) | 0.85 |
PE Ratio | 6.18 |
PEG Ratio | 0.91 |
Wall Street Target Price | 17.0 |
Profit Margin | 4.64% |
Operating Margin TTM | 15.94% |
Return On Assets TTM | 6.63% |
Return On Equity TTM | 4.88% |
Revenue TTM | 257.6M |
Revenue Per Share TTM | 19.68 |
Quarterly Revenue Growth YOY | -12.8% |
Gross Profit TTM | 221.7M |
EBITDA | 62.3M |
Diluted Eps TTM | 0.85 |
Quarterly Earnings Growth YOY | -0.87 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 1.05 |
EPS Estimate Next Quarter | 0.93 |
What analysts predicted
Upside of 197.2%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 236.7M | ↑ 24.92% |
Net Income | 51.9M | ↓ 36.23% |
Net Profit Margin | 21.94% | ↓ 21.05% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 213.3M | ↓ 9.88% |
Net Income | 31.9M | ↓ 38.58% |
Net Profit Margin | 14.96% | ↓ 6.98% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 195.9M | ↓ 8.17% |
Net Income | 14.3M | ↓ 55.14% |
Net Profit Margin | 7.31% | ↓ 7.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 187.8M | ↓ 4.13% |
Net Income | 12.0M | ↓ 16.24% |
Net Profit Margin | 6.38% | ↓ 0.93% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 171.5M | ↓ 8.66% |
Net Income | -8.6M | ↓ 171.96% |
Net Profit Margin | -5.03% | ↓ 11.41% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 316.6M | ↑ 84.56% |
Net Income | 35.6M | ↓ 513.14% |
Net Profit Margin | 11.26% | ↑ 16.29% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 115.9M | ↑ 173.8% |
Net Income | 44.1M | ↓ 811.07% |
Net Profit Margin | 38.02% | ↑ 52.66% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 74.1M | ↓ 36.02% |
Net Income | -9.5M | ↓ 121.45% |
Net Profit Margin | -12.75% | ↓ 50.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 65.9M | ↓ 11.11% |
Net Income | -3.5M | ↓ 62.83% |
Net Profit Margin | -5.33% | ↑ 7.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 60.7M | ↓ 7.89% |
Net Income | 8.2M | ↓ 332.42% |
Net Profit Margin | 13.45% | ↑ 18.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.3M | ↑ 9.24% |
Net Income | 5.8M | ↓ 29.58% |
Net Profit Margin | 8.67% | ↓ 4.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 64.6M | ↓ 2.5% |
Net Income | 5.2M | ↓ 10.19% |
Net Profit Margin | 7.99% | ↓ 0.68% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 270.1M | ↑ 26.45% |
Total Liabilities | 90.9M | ↑ 45.83% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 238.6M | ↓ 11.65% |
Total Liabilities | 77.8M | ↓ 14.38% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 254.6M | ↑ 6.69% |
Total Liabilities | 75.4M | ↓ 3.16% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 253.2M | ↓ 0.54% |
Total Liabilities | 67.2M | ↓ 10.88% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 253.7M | ↑ 0.21% |
Total Liabilities | 77.3M | ↑ 15.03% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 406.2M | ↑ 60.07% |
Total Liabilities | 172.6M | ↑ 123.35% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 320.2M | ↑ 26.18% |
Total Liabilities | 104.2M | ↑ 34.84% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 381.8M | ↑ 19.24% |
Total Liabilities | 143.8M | ↑ 37.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 390.1M | ↑ 2.18% |
Total Liabilities | 154.7M | ↑ 7.58% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 406.2M | ↑ 4.13% |
Total Liabilities | 172.6M | ↑ 11.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 414.2M | ↑ 1.97% |
Total Liabilities | 171.3M | ↓ 0.74% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 404.8M | ↓ 2.26% |
Total Liabilities | 152.8M | ↓ 10.83% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 58.9M | ↑ 10.74% |
Investing Cash Flow | -5.2M | ↓ 88.68% |
Financing Cash Flow | 8.1M | ↓ 124.07% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 52.4M | ↓ 11.09% |
Investing Cash Flow | -133.0K | ↓ 97.44% |
Financing Cash Flow | -88.1M | ↓ 1187.33% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 56.0M | ↑ 6.88% |
Investing Cash Flow | -777.0K | ↑ 484.21% |
Financing Cash Flow | -24.2M | ↓ 72.51% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 49.5M | ↓ 11.59% |
Investing Cash Flow | -18.2M | ↑ 2248.39% |
Financing Cash Flow | -37.9M | ↑ 56.33% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.2M | ↓ 42.99% |
Investing Cash Flow | -5.3M | ↓ 70.83% |
Financing Cash Flow | -28.4M | ↓ 25.03% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 50.7M | ↑ 79.67% |
Investing Cash Flow | -86.8M | ↑ 1531.22% |
Financing Cash Flow | -6.2M | ↓ 78.13% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.6M | ↓ 305.56% |
Investing Cash Flow | -168.0K | ↑ 242.86% |
Financing Cash Flow | -11.4M | ↑ 12.3% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 43.0M | ↓ 358.82% |
Investing Cash Flow | -75.4M | ↑ 44790.48% |
Financing Cash Flow | -536.0K | ↓ 95.28% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.2M | ↓ 130.79% |
Investing Cash Flow | -11.2M | ↓ 85.1% |
Financing Cash Flow | 3.3M | ↓ 714.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 37.6M | ↓ 383.73% |
Investing Cash Flow | -9.0K | ↓ 99.92% |
Financing Cash Flow | 2.4M | ↓ 27.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -33.5M | ↓ 189.23% |
Investing Cash Flow | -12.6M | ↑ 139433.33% |
Financing Cash Flow | 12.6M | ↑ 429.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -126.0K | ↓ 99.62% |
Investing Cash Flow | -6.0K | ↓ 99.95% |
Financing Cash Flow | -6.4M | ↓ 150.7% |
Sell
Neutral
Buy
Eagle Pharmaceuticals Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Eagle Pharmaceuticals Inc. | 16.67% | 6.1% | -69.42% | -87.93% | -89.66% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Eagle Pharmaceuticals Inc. | 6.18 | 6.18 | 0.91 | 0.0 | 0.05 | 0.07 | NA | 19.25 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Eagle Pharmaceuticals Inc. | Buy | $68.0M | -89.66% | 6.18 | 4.64% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Eagle Pharmaceuticals Inc.
Revenue is down for the last 2 quarters, 66.30M → 64.64M (in $), with an average decrease of 2.5% per quarter
Netprofit is down for the last 3 quarters, 8.16M → 5.16M (in $), with an average decrease of 19.9% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 114.9%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 140.5%
Nantahala Capital Management, LLC
AIGH Capital Management, LLC
BlackRock Inc
AQR Capital Management LLC
Vanguard Group Inc
Morgan Stanley - Brokerage Accounts
specialty pharmaceutical company
Organization | Eagle Pharmaceuticals Inc. |
Employees | 134 |
CEO | Mr. Michael Graves |
Industry | Health Technology |
A Spac I Acquisition Corp
$5.72
-0.35%
Keyarch Acquisition Corp
$5.72
-0.35%
Connexa Sports Technologies Inc
$5.72
-0.35%
Us Value Etf
$5.72
-0.35%
First Wave Biopharma Inc
$5.72
-0.35%
Global X Msci Next Emerging
$5.72
-0.35%
Fat Projects Acquisition Corp
$5.72
-0.35%
Capital Link Global Fintech
$5.72
-0.35%
Applied Uv Inc
$5.72
-0.35%